Altana Pharma selects Cyprotex for drug discovery support

UK-based Cyprotex is to provide drug discovery support using its Cloe Screen technology to international pharmaceutical group Altana Pharma, based in Konstanz, Germany. The agreement is to run for a year and has the capacity to be extended to additional assays.

Under the terms of the agreement, Cyprotex will screen batches of Altana compounds across three assays on a monthly basis to provide essential information on their metabolism by the liver. These tests use Cyprotex's high throughput in vitro screening system known as Cloe Screen, which profiles compounds for ADME properties.

Cloe Screen has been targeted at avoiding the significant effort and cost involved in later stage failures by providing a high quality and cost-efficient solution for screening compounds in the early stages of the drug discovery process. Cloe Screen cost efficiencies are due to a highly automated plate-based approach to compound screening which has been developed by Cyprotex scientists.